Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report [PDF]
Case Reports in Ophthalmology, 2016 Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response
Stacey A. Strong +2 more
doaj +5 more sources
Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports [PDF]
, 2020 Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these ...
Avery +30 more
core +4 more sources
Features of aflibercept plus hyperbaric oxygen therapy for diabetic macular edema
Journal of Ophthalmology, 2022 Background: Diabetes mellitus (DM) is a disease characterized by chronic hyperglycemia and a cascade of pathological vascular alterations leading to diabetic retinopathy (DR) and diabetic macular edema (DME).
V. O. Drozdov, V. M. Sakovych
doaj +1 more source
Integrated results from the COPERNICUS and GALILEO studies. [PDF]
, 2017 OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO.
Ahlers, Christiane +13 more
core +3 more sources
Aflibercept clearance through the drainage system in a rat model
International Journal of Retina and Vitreous, 2021 Background As intravitreal anti-VEGF injections became the mainstay of treatment for many retinal diseases, the cause of a secondary sustained elevated intraocular pressure is still unclear.
Yariv Keshet +6 more
doaj +1 more source
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]
, 2013 Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO +15 more
core +1 more source
Translational Oncology, 2019 Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents.
Richard A. Forsgård +8 more
doaj +1 more source
European medicines agency approval summary: zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer [PDF]
, 2017 On 1 February 2013, a marketing authorisation valid throughout the European Union was issued for aflibercept (Zaltrap) in combination with irinotecan/5-fluorouracil/ folinic acid chemotherapy for the treatment of adults with metastatic colorectal cancer ...
Caleno, Mariapaola +8 more
core +1 more source
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells [PDF]
, 2016 Indexación: Web of ScienceTumor angiogenesis is widely recognized as one of the hallmarks of cancer. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Carrasco-Avino, G +4 more
core +1 more source
Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
Molecular Therapy: Methods & Clinical Development, 2023 Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in the aging population, with vascular endothelial growth factor (VEGF) playing a key role. Treatment with recombinant anti-VEGFs is the current standard of care; however,
Sharifah Iqball +8 more
doaj +1 more source